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Abstract
Background: Despite multiple pharmacological interventions, many people with bipolar disorder (BD) experience
substantial residual mood symptoms, even in the absence of severe mood episodes, which have a negative impact
on the course of illness and quality of life. Limited data are available on how to optimize treatment for BD,
especially for those who suffer from persistent and residual depressive symptoms. Preliminary evidence suggests
Mindfulness-Based Cognitive Therapy (MBCT) as a psychological treatment option for BD. This study aims to
investigate whether adding MBCT to treatment as usual (TAU) will result in symptomatic and functional
improvements in adults with BD compared to TAU alone.
Methods/design: This study is a prospective, evaluator blinded, multicenter, randomized controlled trial of
MBCT + TAU and TAU alone in 160 adults with bipolar type I and type II. Assessments will be conducted at
baseline (T0), mid-treatment (Tmid), and at 3 (T1), 6 (T2), 9 (T3), 12 (T4), and 15 (T5) months follow-up. Primary
outcome is post-treatment severity of depressive symptoms (Inventory of Depressive Symptomatology- Clinician
administered). Secondary outcomes are severity of (hypo) manic symptoms, anxiety, relapse rates, overall
functioning, positive mental health, and cost-effectiveness. As possible mediators will be assessed rumination of
negative affect, dampening and rumination of positive affect, mindfulness skills, and self-compassion.
Discussion: This study will provide valuable insight into the (cost-)effectiveness of MBCT on clinician- and self-rated
symptoms of BD, relapse rates, positive mental health, and overall functioning.
Trial registration: NCT03507647. Registered 25th of April 2018.
Keywords: Mindfulness-based cognitive therapy, Bipolar disorder, Randomized controlled trial; study protocol
Background
Bipolar disorder (BD) is a disabling, chronic condition
characterized by recurrent (hypo) manic, depressive,
and/or mixed episodes, affecting approximately 1.2% of
adult men and 1.4% of adult women in the Netherlands
[1]. BD belongs to the leading causes of years lost due to
disability, and is associated with considerable economic,
occupational, and social burden [2–4]. Illness-related
disability is mostly accounted for by depressive symp-
toms and episodes [5, 6]. Similar to individuals with
major depression, people with BD demonstrate a ten-
dency to ruminate in response to negative affect [7].
This appears to create a vicious cycle of ruminative
thinking, decreased interest and motivation, and a loss
of positive affect, resulting in an increase in depressive
symptoms. Furthermore, people with BD show a ten-
dency to ruminate in response to positive affect as well
[8], which has been found to be correlated with in-
creased (hypo) manic symptoms [9, 10]. Despite multiple
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pharmacological options, people with BD experience
substantial residual mood symptoms about half the time.
Approximately 60% of people with BD relapse in a full--
blown mood episode within two years after recovering
from a previous mood episode [6, 11–13]. These persist-
ent mood symptoms affect the course of BD and quality
of life negatively [14]. Therefore, the management of BD
requires additional psychological interventions [15, 16].
However, most psychological interventions used in the
treatment of BD, such as Cognitive Behavioral Therapy
(CBT), are more effective for people with major depres-
sion or in people with BD who suffered less than 12 mood
episodes [16–18]. Limited data are available on how to
optimize treatment for the whole population of people
with BD, especially for those who suffer from persistent
and residual mood symptoms.
Mindfulness-based approaches have recently been
adopted to the Dutch national guidelines of bipolar dis-
orders, adopting Mindfulness-Based Cognitive Therapy
(MBCT) as a psychological treatment option in order to
prevent depressive relapse in people with BD [19].
MBCT integrates meditative practices with elements of
cognitive therapy and aims toward people developing a
capacity to be aware of (distressing) thoughts, feelings,
and bodily sensations in a non-judgmental way [20, 21].
MBCT has been shown promising results in a wide
range of psychiatric disorders [22], including major
depression (e.g. [23, 24]), and a limited effect in anxiety
disorders [25]. Even though MBCT was adopted as a
treatment option to the Dutch national guidelines of
bipolar disorders, evidence about its effectiveness in BD
is still scarce. There are a number of small pilot studies
showing either reductions in severity of depressive and/
or anxiety symptoms [26–28], or no improvement in
depressive symptoms [29]. To date, only one randomized
controlled trial of MBCT for BD has been conducted in
95 participants [30]. This study of Perich et al. found sig-
nificant improvements in anxiety symptoms, but not in
depressive symptoms after MBCT over the course of a
12-month follow-up period. However, they included
remitted adults with BD only, which may have limited
the possible range of symptom reduction and the clinical
representativeness of this study. Furthermore, the drop-
out rates at 12-month follow-up were high, with almost
65% of participants not completing follow-up measures.
The current trial will provide the first high-level
evidence of the effectiveness of MBCT in addition to
treatment as usual (TAU) compared to TAU alone in
euthymic or depressed individuals with BD, by including
follow-up assessments up to 12months after completion
of treatment and keeping close track of treatment adher-
ence and occurrence of (serious) adverse reactions.
The primary aim of this study is to compare post-
intervention depressive symptom severity after MBCT +
TAU and TAU alone. The secondary aims are to investi-
gate whether MBCT is effective in reducing long-term
depressive symptoms, and post-treatment and long-term
(hypo) manic and anxiety symptom severity, relapse
rates, and increasing overall functioning and positive
mental health. Previous research has shown that the re-
lationship between mindfulness practice and improve-
ment in psychological symptoms is mediated by
mindfulness skills, self-compassion, and rumination [31].
Therefore, it is expected that improvements in severity
of depressive symptoms is mediated by mindfulness
skills, self-compassion, and rumination of negative affect,
and dampening and rumination of positive affect. More-
over, since there is some evidence that certain psycho-
logical interventions become less effective for people
with BD who experienced 12 or more mood episodes
[18], the current trial will investigate whether MBCT
will be more effective in people with BD with less than
12 mood episodes compared to people with BD who
suffered 12 or more mood episodes. Finally, from a soci-
etal perspective, the current study will assess whether
implementing MBCT + TAU is cost-effective compared
to TAU alone. It is expected that adding MBCT to TAU
will result in a reduction of medical and societal costs.
In conclusion, the current study will be the first
randomized controlled trial of MBCT for BD in the
Netherlands and to the best of our knowledge the
second RCT overall, providing high-level evidence of the
relative long-term effectiveness of MBCT + TAU versus
TAU for adults with BD. It will be offered in a
multi-centre setting, using several outcome measures,
including cost-effectiveness. If (cost-)effective, MBCT
might widen the array of evident psychological interven-
tions for BD.
Methods/design
Study design
This study is a prospective, evaluator blinded, multicen-
ter, randomized controlled trial of MBCT + TAU versus
TAU alone. Assessments will be conducted at baseline
(T0), mid-treatment (Tmid), and at 3 (T1), 6 (T2), 9
(T3), 12 (T4), and 15 (T5) months follow-up. Partici-
pants randomized to the TAU condition will be able to
participate in a MBCT intervention after they com-
pleted the study (15 months). The study protocol has
been approved by the ethical review board CMO
Arnhem – Nijmegen and is registered under number
NL63319.091.17.
Setting
The MBCT interventions will be provided at the
Radboud University Medical Centre in Nijmegen, and at
five specialized outpatient clinics for bipolar disorders in
the Netherlands, including Altrecht (Utrecht), Pro
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Persona (Arnhem/Nijmegen/Tiel/Ede); Dimence (Zwolle),
PsyQ (Rotterdam) and GGZ Breburg (Tilburg/Breda).
Study population
The study population will consist of adults (18 years or
older) with BD. The following inclusion criteria will be
applied: 1) a confirmed diagnosis of bipolar I or bipolar
II disorder, according to the Diagnostic and Statistical
Manual of Mental Disorders – 5th edition (DSM-5) [32]
and confirmed by using the Structured Clinical Inter-
view for DSM-IV Axis I Disorders (SCID-I) [33]; 2)
having suffered at least two confirmed lifetime depres-
sive episodes, either current or in (partial) remission at
baseline; 3) having suffered at least one mood episode
(either depressive and/or (hypo)manic) within the year
prior to baseline; and 4) a Young Mania Rating Scale
(YMRS) [34] score of 12 or lower. The following exclu-
sion criteria will be applied: 1) insufficient comprehen-
sion of the Dutch language; 2) previous participation in
an eight-week mindfulness-based intervention; 3) having
suffered a manic episode within three months before
baseline; 4) a lifetime diagnosis of schizophrenia or schi-
zoaffective disorder, current substance abuse disorder,
organic brain syndrome, or antisocial or borderline
personality disorder; 5) increased risk of suicide or ag-
gression; 6) additional psychological interventions, such
as CBT or trauma therapy, at the time of recruitment,
baseline assessment or between T0 and T1; and 6) the
presence of a concurrent significant medical condition
impeding the ability to participate.
Procedure
Clinicians from the participating outpatient clinics will
provide the first screening by selecting patients from
their caseload who will most likely meet the in- and
exclusion criteria of this study. To minimize the risk of
“gatekeeping”, they will be asked to only exclude patients
not meeting in- or exclusion criteria and to provide the
reasons for exclusion on a form. Subsequently, poten-
tially eligible participants will receive an invitation letter
and information leaflet from their attending clinicians,
after which they can contact the research team. Partici-
pants will be recruited by self-selection as well, for ex-
ample by media advertisements by the Dutch patient
association of adults with BD (Vereniging voor Manisch
Depressieven en Betrokkenen). After verbal consent is
obtained, participants will be invited for a screening by
telephone to assess eligibility. Eligible participants will
be invited for a research interview with a trained
research assistant, where written informed consent will
be obtained. During the research interview, participants
will be thoroughly screened for in- and exclusion criteria
with use of the SCID-I and YMRS. Subsequently, if
participants are still eligible to participate, they will be
invited for the baseline assessment, which consists of
several clinician administered measures and self-report
questionnaires (see Table 2). Blinded assessments of
clinician-rated measurements will be obtained by trained
research assistants at 3, 6, 9, 12, and 15months
follow-up. The 6, 9, and 12months follow-up assess-
ments will be conducted by telephone. Self-report ques-
tionnaires will be obtained at baseline, four weeks after
start of the MBCT intervention (mid-treatment) and at
3, 6, 9, 12, and 15months follow-up. Figure 1 provides a
flowchart of the study procedures from referral to final
assessment.
Randomization and blinding
Randomization will be computerized using an Electronic
Data Capture (EDC) program (CASTOR: https://www.
castoredc.com/). Randomization will be stratified for 1)
setting; 2) gender; 3) depression status (current vs. re-
mitted); and 4) bipolar type I or II. In order to ensure
balanced groups, we will use block randomization with
block sizes of either 2, 4, or 6. Research assistants on site
will be blinded for allocation and participants will be
asked not to talk about their group allocation during
assessments.
Treatment as usual
Usual care of people with BD typically consists of
pharmacotherapy (usually provided and monitored by a
psychiatrist), and psycho-education and self-management
interventions, e.g. maintaining biopsychological rhythm,
detection and management of early signs of mood dysreg-
ulation, and improving coping skills (usually provided and
monitored by a psychiatric nurse) [19]. Because of the
clinical representativeness, we will not restrict TAU in any
way and, therefore, participants will be allowed to switch,
taper or augment their medication. It is expected that a
large majority of participants in the current study will
receive some form of pharmacotherapy. A careful record
of this will be kept in order to examine and control for
possible differences between the two groups.
Intervention
The MBCT program developed in the current study is
an adaptation of the original MBCT intervention for
recurrent depression by Segal, Williams, and Teasdale
[20]. The MBCT program was adapted to the needs of
people with BD in terms of tailoring psycho-educative
elements to BD (e.g. adding information and exercises
focusing on mania), implementing more movement
exercises, introducing the three-minute breathing space
earlier and more often in the program, adding a partner
session (session 6), and repeatedly bringing focus to
self-care. These adaptations were based on qualitative
feedback of 15 individuals with BD who participated in
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two consecutive pilot groups of traditional MBCT at the
Radboud University Medical Centre (Nijmegen, the
Netherlands). These qualitative data, focusing on bar-
riers and facilitators, were collected during two focus
groups.
The group-based MBCT program consists of eight
weekly 2.5 h sessions, a 6-h silent day between session
six and seven, and home assignments to practice both
formal (e.g. body scan, sitting meditation) and informal
meditative exercises (e.g. mindful routine activity) about
45 min per day. All MBCT interventions will be con-
ducted at the respective mental health sites, with each
group consisting of 8–10 participants. Table 1 provides
an overview of the MBCT program as applied in the
current study.
Mindfulness teachers
Each MBCT intervention will be taught by two teachers,
of whom at least one will qualify the advanced criteria of
the Association of Mindfulness Based Teachers in the
Netherlands and Flanders, which are in concordance
with the good practice guidelines of the UK Network for
Mindfulness-Based Teachers [35]. These criteria include
the following: 1) a minimum of 150 h of education in
MBSR/MBCT background and theory, training in formal
and informal meditative practices, psycho-education and
Recruitment via mental health professionals’ referrals or self-referrals.
Interested individuals screened by telephone to assess global eligibility after verbal consent is obtained.
Does patient (probably) meet inclusion (and not exclusion criteria)? No Exclude
Yes
Study procedure explained in detail and study information is provided. Patients get two weeks (or 
longer if needed) to decide whether or not to participate.
Patient still interested in participation? No Exclude
Yes
Eligible and informed consent obtained? No Exclude
Yes
T0 assessment (baseline)
Randomization (stratification variables: research centre; gender; depression status (current versus 
remitted); type of Bipolar Disorder
TAU + MBCT TAU
MBCT intervention 
(8 weeks) 
Intermediate measures 
(after 4 weeks)
T5 assessment (15 months)
T4 assessment (12 months)
T3 assessment (9 months)
T2 assessment (6 months)
T1 assessment (3 months)
MBCT + TAU
Patient is invited for a research interview in which the in- and exclusion criteria are assessed in detail using 
SCID-I and YMRS. Written informed consent is collected.
Fig. 1 Flowchart of study procedures from referral to final assessment
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inquiry, supervision and teaching a MBSR/MBCT
including a reflection report; 2) relevant professional
training; 3) minimum of three years of practicing medi-
tation regularly and attending retreats; 4) having
attended a MBSR/MBCT intervention as a participant;
5) continued training; and 6) giving a minimum of two
MBCT/MBSR interventions per two years. All mindful-
ness teachers will receive additional training in the study
protocol at the start of the trial. Supervision meetings
will be organized repeatedly during the intervention
phase of the trial. Teacher competency will be assessed
by the Mindfulness-Based Interventions – Teacher
Assessment Criteria (MBI-TAC) [36]. Videotapes of a
random selection of sessions will be assessed by asses-
sors who are familiar with the MBCT program, and are
proficient mindfulness teachers themselves (level 5) who
have received training in the use of these assessment
criteria. An early study of the psychometric properties of
the MBI-TAC suggests it has good reliability, face
validity, and promising evidence of validity [37].
Outcome measures
Primary outcome measures
Table 2 provides an overview of the assessments. The
primary outcome measure will be the post-intervention
(3 months follow-up) total score on the Inventory of
Depressive Symptomatology – Clinician administered
(IDS – C), a 30-item clinician administered scale to as-
sess depressive symptom severity [38]. Items are scored
on a 0–3 point scale, with total score ranges from 0 to
84 (where < 13 = not depressed, 14–25 =mildly de-
pressed, 26–38 =moderately depressed, 39–48 =mark-
edly depressed, and 49 > severely depressed). The
psychometric properties of the IDS-C have been shown
Table 1 Overview of MBCT sessions
Theme of session Mindfulness exercises Didactic teaching Homework assignments
1. Automatic pilot • Raisin exercise
• Body scan
• Three-minute breathing space
• Bipolar disorder
• Rationale for mindfulness
• Body scan
• Mindful eating
• Mindful routine activity
• Three-minute breathing space
2. Dealing with
barriers
• Awareness of surroundings
• Body scan
• Sitting meditation – focus on breath
• Three-minute breathing space
• Relationship between
thoughts and feelings
• Body scan
• Three-minute breathing space
• Mindful routine activity
• Pleasant events calendar
3. Mindfulness of the
breath
• Sitting meditation – focus on breath and body
• Three-minute breathing space
• Floor yoga
• Awareness of pleasant events
• Automatic positive thoughts
(mania)
• Recognition and managing
core symptoms of mania
• Sitting meditation
• Floor yoga
• Mindful routine activity
• Unpleasant events calendar
• Three-minute breathing space
4. Staying present • Sitting meditation – focus on breath, body, sounds,
and thoughts
• Three-minute breathing space
• Mindful walking
• Awareness of unpleasant
events
• Automatic negative thoughts
• Recognition and managing
core symptoms of depression
• Sitting meditation/ mindful
walking/ floor yoga/ body scan
• Three-minute breathing space
(regular)
• Three-minute breathing space
(coping)
• Stressful events calendar
5. Allowing and
letting be
• Sitting meditation –focus on breath, body, sounds,
and thoughts
• Standing yoga
• Three-minute breathing space
• Acceptance
• Stress
• Helping and non-helping
thoughts
• Sitting meditation
• Standing yoga
• Three-minute breathing space
(coping)
• Communication events
calendar
6. Mindful
communication
(partner session)
• Standing yoga
• Three-minute breathing space
• Mindfulness and bipolar
disorder
• Communication – listening
and speaking
• Sitting meditation/ mindful
walking/ floor yoga/ body scan
• Three-minute breathing space
• Creating crisis intervention
action plan
Silent day - 6 hours
7. Taking care of
yourself
• Sitting meditation – focus on breath, body, sounds,
thoughts, emotions, and choiceless awareness
• Recognizing symptoms of
relapse
• Keeping in balance
• Relapse prevention plan
• Sitting meditation/ mindful
walking/ floor yoga/ body scan
• Three-minute breathing space
• Adjusting relapse prevention
plan Self-evaluation
8. The rest of your life • Three-minute breathing space
• Body scan
• Three-minute breathing space
• Preventing relapse
• Maintaining practice
• Reflection
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to be highly acceptable in samples of 544 outpatients
with major depression and 402 outpatients with BD [39].
Secondary outcome measures
The Young Mania Rating Scale (YMRS) [34] will be used
to assess (hypo) manic symptom severity. The YMRS is
an 11-item clinician administered scale, with a total
score range of 0 to 60 (where ≤12 indicates remission,
13–19 =minimal symptoms, 20–25 =mildly manic, 26–
37 =moderately manic, and 38–60 = severely manic).
The psychometric properties of the YMRS have been
shown to be adequate [34].
The Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I) [33] will be used to retrospectively
assess the occurrence of depressive and/or (hypo)manic
relapses in the past three months at each assessment.
The psychometric properties of the Dutch translation of
the SCID-I have been shown to be excellent [40].
The Prospective Life Chart, self-report [41] will be used
for participants to daily document the course and sever-
ity of recurrent mood episodes in order to gain more
fine-grained information about the severity of (hypo)-
manic and/or depressive symptoms over time. The psy-
chometric properties of the Life Chart have been shown
to be adequate [41].
The Altman Self-Rating Mania Scale (ASRM) [42] will
be used to assess the presence and severity of (hypo)-
manic symptoms during the intermediate measurements
(4 weeks after start MBCT). The ASRM is a 5-item
self-report questionnaire with score ranges from 0 to 20
(where 6 ≥ indicates a high probability of a (hypo)manic
condition). The psychometric properties of the ASRM
have been shown to be good [42].
The Quick Inventory of Depressive Symptomatology
(QIDS-SR) [43] will be used to assess depressive symp-
tom severity during the intermediate measurements (4
weeks after start MBCT). The QIDS-SR is a 16-item
self-report questionnaire with total score ranges from 0
to 27. The psychometric properties of the QIDS-SR have
been shown to be adequate [43].
The State/Trait Anxiety Inventory (STAI) [44] will be
used to assess severity of anxiety symptoms. The
STAI is a 20-item, self-report measure with a total
score range of 20 to 80. The psychometric properties
of the Dutch translation of the STAI have been
shown to be adequate [45].
The Functioning Assessment Short Test (FAST) [46] will
be used to assess overall functioning. The FAST is a
24-item measure that assesses impairment or disability in
six specific areas of functioning, including 1) autonomy; 2)
occupational functioning; 3) cognitive functioning; 4) fi-
nancial issues; 5) interpersonal relationships; and 6) leisure
time. Psychometric properties of the FAST and its ability
to detect differences between euthymic and acute bipolar
patients have been shown to be excellent [46].
The Mental Health Continuum – Short form (MHC-SF)
[47] will be used to assess emotional, psychological, and
social well-being. The MHC-SF is a 14-item measure with
a total score range of 0 to 70. The psychometric properties
of the MHC-SF have been shown to be adequate [47].
Table 2 Overview of assessments
T0
(baseline)
Tmid
(4 weeks)
T1
(3 months)
T2
(6 months)
T3
(9 months)
T4
(12 months)
T5
(15 months)
Primary outcome
IDS-C Depressive symptoms x x x x x x
Secondary outcomes
YMRS (Hypo)manic symptoms x x x x x x
SCID-I Relapse x x x x x x
ASRM (Hypo)manic symptoms x
QIDS-SR Depressive symptoms x
STAI Anxiety symptoms x x x x x x
FAST Overall functioning x x x x x x
MHC-SF Positive mental health x x x x x x x
FFMQ Mindfulness x x x x x x x
SCS-SF Self-compassion x x x x x x x
RPA-NL Responses to positive affect x x x x x x x
RRS-EXT Brooding x x x x x x x
Cost-effectiveness
EQ-5D-5L Quality of life and quality adjusted life years x x x x x x
TiC-P Costs associated with illness x x x x x x
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The brooding subscale of the extended version of the
Ruminative Response Scale (RRS-EXT) [48] will be used
to assess levels of brooding, also known as rumination.
The brooding subscale consists of five items and has
been shown to have adequate psychometric properties
[48].
The Reponses to Positive Affect Questionnaire - Dutch
Version (RPA-NL) [9] will be used to assess responses to
positive affective states. The RPA-NL is a 17-item
self-report questionnaire consisting of three subscales,
including: 1) dampening of positive affect; 2) self-focused
positive rumination; and 3) emotion-focused positive ru-
mination. The psychometric properties of the English [9]
and Dutch [10] version of the RPA have been shown to be
adequate.
The Five Facet Mindfulness Questionnaire - Short
Form (FFMQ-SF) [49], a 24-item questionnaire, will be
used to assess different aspects of mindfulness, includ-
ing: 1) observing, 2) describing, 3) acting with aware-
ness, 4) non-judging of inner experiences, and 5)
non-reactivity to inner experiences. The psychometric
properties of the FFMQ-SF have been shown to be
adequate [49].
The Self Compassion Scale – Short form (SCS-SF) [50]
will be used to assess levels of self-compassion. The
SCS-SF is a 12-item measure that consists of three
concepts that are related to self-compassion, including
1) self-kindness versus self-judgment; 2) common
humanity versus isolation; and 3) mindfulness versus
over-identification. The psychometric properties of the
SCS-SF have been shown to be adequate [50].
Cost-effectiveness
The EQ-5D-5 L [51] will be used to measure the Quality
of Life and the Quality Adjusted Life Years. The
EQ-5D-5 L consists of five dimensions, including: 1) mo-
bility; 2) self-care; 3) usual activities; 4) pain/discomfort;
and 5) anxiety/depression. The psychometric properties
of the EQ-5D-5 L have been shown to be adequate [52].
The Trimbos/iMTA questionnaire for costs associated
with psychiatric illness (TiC-P) [53] will be used to as-
sess recourse use, such as use of care, medication, and
illness related to work. It measures both direct costs, i.e.
care consumption of people suffering from psychiatric
illness, and indirect costs, i.e. costs associated with pro-
duction loss. The psychometric properties of the TiC-P
have been shown to be adequate [54].
Adherence
Participants in the MBCT + TAU condition will be
asked to daily document adherence to mindfulness
practice. For this purpose, a calendar was designed on
which participants will be asked to fill out the number
of minutes daily spent on formal and informal
mindfulness practices during the intervention. During
follow-up, adherence will be retrospectively determined
using a short questionnaire, asking which mindfulness
exercises they still practice, how often and for how long.
Participants in both conditions will be asked to docu-
ment their medication adherence as well, using the Pro-
spective Life Chart, self-report [41].
Safety monitoring
In accordance with Good Clinical Practice guidelines,
(serious) adverse events, both related and unrelated to
the study, will be reported. During follow-up assess-
ments, participants will be explicitly asked whether they
have experienced any undesirable (medical) incidents
during the study period. The occurrence, intensity and
duration of these (serious) adverse events will be
documented carefully. Furthermore, participants in the
MBCT + TAU condition will be asked to daily docu-
ment any (serious) adverse reactions ((S)AR) they might
experience in response to mindfulness practice during
the MBCT intervention. For this purpose, a log was
designed on which twelve of the most likely (S)AR
related to mindfulness practice for bipolar patients are
documented. These (S)AR are inspired by earlier studies
on adverse effects in meditation [55–57] and include the
following: 1) re-experiencing of traumatic memories; 2)
overwhelming or uncontrollable feelings of depression;
3) uncontrollable feelings of happiness or grandiosity; 4)
uncontrollable feelings of irritability; 5) sudden (in-
crease) of anxiety or panic; 6) feelings of derealization;
7) feelings of depersonalization; 8) feelings of distrust to
others; 9) feelings of doubt towards the self; 10) visual
hallucinations; 11) auditory hallucinations; and 12)
unusual physical sensations. Participants will be asked to
indicate how often they experienced certain (S)AR,
whether they consider these reactions to be causally
related to meditation, the intensity of these (S)AR in a
scale from 1 to 10 (were 1 = low intensity and 10 = high
intensity), and how they reacted in response to this
(S)AR. In the long-term, if not reported spontaneously,
(S)AR will be retrospectively determined during qualita-
tive interviews.
Statistical analysis
Sample size calculation
The sample size calculation was based on the estimated
change in depressive symptom severity from pre- to
post-intervention, as reported in a similar study about
the efficacy of MBCT in recurrent depression conducted
at the Radboud University Medical Centre [24]. This
study found an effect size of 0.5 for reduction of depres-
sive symptoms in people with recurrent (unipolar) de-
pression, who were partly in remission (n = 124), or
partly currently depressed (n = 58). Based on a two-sided
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test with an alpha of .05 and a power of 80%, with an
estimated effect size of 0.5, including a design-factor of 1
– r2 (0.75), and taking account of a conservative estimate
of 40% loss to follow-up, the current study will intend to
recruit 160 patients (intervention group n = 80, control
group n = 80).
Statistical analysis
All data will be analyzed and reported according to the
CONSORT guidelines [58], using intention-to-treat and
per-protocol analyses. Inadvertently unequally distrib-
uted baseline parameters between the conditions will be
included as covariates. Assumptions of normality will be
checked and, in case of lack of normality, the boot-
strapping procedure will be used to account for this
problem [59]. Sensitivity analyses will be conducted
with different scenarios of imputed data sets to exam-
ine the influence of missing data on the pattern of
outcomes.
Primary analysis will be aimed at comparing depressive
symptom severity at three months after baseline between
MBCT + TAU and TAU. In order to investigate consoli-
dation of treatment effect, outcomes will be assessed at
6, 9, 12, and 15months follow-up. Secondary analyses
will be aimed at comparing the treatment effects of
MBCT + TAU versus TAU on (hypo)manic and anxiety
symptom severity, relapse rates, and overall functioning
and positive mental health, post-intervention and up to
15months follow-up. Multilevel analysis will be used to
account for the cluster-randomized design and, there-
fore, the hierarchical structure of the data, with outcome
variables at pre- and postmeasurements at the lowest
level, nested within individuals, nested within treatment
groups (in the intervention condition), and nested within
condition (MBCT + TAU versus TAU). Mediation ana-
lysis will be conducted to investigate whether possible
clinical effects of MBCT in primary outcome measures
are mediated by rumination on positive and negative
affect, mindfulness skills, and self-compassion [60]. Add-
itional analyses will be performed within subgroups who
suffered < 12 or ≥ 12 mood episodes, and within sub-
groups with and without a current depressive episode.
The economic evaluation will be based on the general
principles of a cost-utility, cost-effectiveness, and
budget-impact analysis, comparing MBCT + TAU versus
TAU. Primary outcomes of the economic evaluation will
be quality adjusted life years (QALYs), treatment re-
sponse (scores on IDS-C), and both direct and indirect
costs [61]. The incremental cost-effectiveness ratio
(ICER) will be computed using non-parametric boot-
strap methods to account for skewness of the cost-data.
The cost-effectiveness ratio will be stated in terms of
costs per outcome rate (IDS-C), while the cost-utility ra-
tio will focus on the cost per QALY gained. The budget
impact analysis (BIA) will be used as outlined by the
IPSOR Task Group [62, 63] to assess how health care
budgets change when MBCT is offered over a range of
implementation levels. The BIA will be conducted from
various perspectives, including: 1) the societal perspec-
tive (i.e. productivity loss); 2) the perspective of the
public purse; and 3) the perspective of the health care
insurer. In each perspective different scenarios will be
assessed, in which the intervention is offered to 40, 60,
and 80% of the target group, and an extreme scenario in
which 100% of the target group will be receiving MBCT
interventions. These scenarios will be compared with a
base-case scenario where 0% of the target group is of-
fered MBCT (reflecting TAU). The BIA will be based on
a health-economic simulation excel model, based on
modeling techniques outlined by Briggs, Claxton, and
Sculpher [64], and following IPSOR modeling guidelines
[65]. The BIA will be conducted according to the Dutch
guidelines [66], taking into account the complexity and
dynamics of clinical practice and specific characteristics
of the Dutch health care system.
Discussion
The current trial will be the first properly powered,
multicenter, randomized controlled trial of MBCT for
BD in the Netherlands and the second world-wide. It
will provide high-level evidence of the relative long-term
effectiveness of MBCT + TAU compared to TAU alone
by including follow-up measurements up to 15months
en keeping close track of treatment adherence and oc-
currence of (serious) adverse reactions. The study will be
conducted in five specialized clinics for bipolar disorders
in order to enhance generalizability. From a societal per-
spective, the current trial will assess whether adding
MBCT to TAU is cost-effective. This study will provide
valuable insight into the accessibility and (cost-) ef-
fectiveness of MBCT in terms of clinician-rated and
self-rated symptoms of BD, relapse rates, positive
mental health, and overall functioning. Furthermore,
this study might elucidate in which stage(s) of the ill-
ness MBCT might be helpful in relieving residual
mood symptoms.
Abbreviations
(S)AR: (serious) adverse reaction; BIA: Budget impact analysis; CBT: Cognitive
behavioral therapy; CHIME: Comprehensive inventory of mindfulness
experience; DSM-5: Diagnostic and statistical manual of mental disorders –
5th edition; FAST: Functioning Assessment Short Test; ICER: Incremental cost-
effectiveness ratio; MBCT: Mindfulness-Based Cognitive Therapy; MBI-
TAC: Mindfulness-Based Interventions – Teacher Assessment Criteria; MHC-
SF: Mental Health Continuum- Short Form; OASIS: Overall anxiety severity
and impairment scale; QALY: Quality adjusted life years; SCID-I: Structured
Clinical Interview for DSM-IV Axis I Disorders; SCS-SF: Self-Compassion Scale –
Short Form; STAI: State/Trait Anxiety Inventory; TAU: Treatment as usual; TiC-
P: Trimbos/iMTA questionnaire for costs associated with psychiatric illness;
YMRS: Young Mania Rating Scale
Hanssen et al. BMC Psychiatry          (2019) 19:130 Page 8 of 10
Acknowledgements
Not applicable.
Funding
This study is externally funded by a grant from ZonMw, the Netherlands
Organization for Health Research and Development (Grant Number:
843002803) awarded to prof. dr. A. E. M. Speckens and dr. M. J. Huijbers. The
funding agency will have no role in data collection, management, analysis,
interpretation of data; writing of the report; or the decision to submit the
report for publication.
Availability of data and materials
Not applicable.
Authors’ contributions
All authors contributed to the design of the study. AES is the principal
investigator. IH drafted this paper, which was supplemented by all other
authors. IH, MH, RK, MLvB, ER, and AS will be involved in recruiting
participants. IH will be responsible for the logistics and data collection. SE
contributed to the design of cost-effectiveness study and MW contributed to
the implementation strategy. All authors have read and approved the final
paper.
Ethics approval and consent to participate
The study protocol has been approved by the ethical review board CMO
Arnhem – Nijmegen and is registered under number NL63319.091.17. Both
verbal and written consent to participate will be obtained.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Psychiatry, Centre for Mindfulness, Radboud University
Medical Centre, Postbus 9101, 6500, HB, Nijmegen, The Netherlands.
2Donders Institute for Brain, Cognition and Behaviour, Radboud University,
Nijmegen, The Netherlands. 3Department of Mood Disorders, Pro Persona,
Mental Health Care, Tarweweg 2, 6534, AM, Nijmegen, The Netherlands.
4Altrecht, Institute for Mental Health Care, Outpatient clinic for Bipolar
Disorders, Nieuwe Houtenseweg 12, 3524, SH, Utrecht, the Netherlands.
5Dimence Mental Health, Center for Bipolar Disorders, Pikeursbaan 3, 7411,
GT, Deventer, The Netherlands. 6Trimbos-instutuut, Postbus 725, 3500, AS,
Utrecht, the Netherlands. 7Radboud University Medical Centre, Institute for
Quality in Health Care, Postbus 9101, 6500, HB, Nijmegen, the Netherlands.
8Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam
Public Health Research Institute, Oldenaller 1, 1081, HJ, Amsterdam, the
Netherlands.
Received: 24 October 2018 Accepted: 11 April 2019
References
1. de Graaf R, Ten Have M, van Gool C, van Dorsselaer S. Prevalence of mental
disorders and trends from 1996 to 2009. Results from the Netherlands
mental health survey and incidence Study-2. Soc Psychiatry Psychiatr
Epidemiol. 2012;47(2):203–13.
2. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and
II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83.
3. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price.
In: The cost of mental health care in England to 2026: King's Fund; 2008.
4. Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, Wittchen H-
U. Prevalence and burden of bipolar disorders in European countries. Eur
Neuropsychopharmacol. 2005;15(4):425–34.
5. Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the
longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003;5(6):417–8.
6. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC,
Rice JA, Keller MB. The long-term natural history of the weekly symptomatic
status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–7.
7. Johnson SL, McKenzie G, McMurrich S. Ruminative responses to negative
and positive affect among students diagnosed with bipolar disorder and
major depressive disorder. Cogn Ther Res. 2008;32(5):702–13.
8. Hanssen I, Regeer EJ, Schut D, Boelen PA. Ruminative and dampening
responses to positive affect in bipolar disorder and major depressive
disorder. Compr Psychiatry. 2018;85:72–7.
9. Feldman GC, Joormann J, Johnson SL. Responses to positive affect: a self
report measure of rumination and dampening. Cogn Ther Res. 2008;32(4):
507–25.
10. Raes F, Daems K, Feldman GC, Johnson SL, van Gucht D. A psychometric
evaluation of the dutch version of the responses to positive affect
questionnaire. Psychologica Belgica. 2009;49(4):293–310.
11. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, Endicott J,
Keller M. Long-term symptomatic status of bipolar I vs. bipolar II disorders.
nt J Neuropsychopharmacol. 2003;6(2):127–37.
12. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter
TA, Miklowitz DJ, Otto MW, Gyulai L. Predictors of recurrence in bipolar
disorder: primary outcomes from the systematic treatment enhancement
program for bipolar disorder (STEP-BD). Am J Psychiatr. 2006;163(2):217–24.
13. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in
bipolar disorder. Am J Psychiatry. 1995;152(11):1635.
14. Gutiérrez-Rojas L, Gurpegui M, Ayuso-Mateos JL, Gutiérrez-Ariza JA, Ruiz-
Veguilla M, Jurado D. Quality of life in bipolar disorder patients: a comparison
with a general population sample. Bipolar Disord. 2008;10(5):625–34.
15. Vieta E, Colom F. Psychological interventions in bipolar disorder: from
wishful thinking to an evidence-based approach. Acta Psychiatr Scand.
2004;110(422):34–8.
16. Oud M, Mayo-Wilson E, Braidwood R, Schulte P, Jones SH, Morriss R, Kupka R,
Cuijpers P, Kendall T. Psychological interventions for adults with bipolar disorder:
systematic review and meta-analysis. Br J Psychiatry. 2016;208(3):213–22.
17. Scott J, Garland A, Moorhead S. A pilot study of cognitive therapy in bipolar
disorders. Psychol Med. 2001;31(3):459–67.
18. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R,
Hayhurst H. Cognitive–behavioural therapy for severe and recurrent bipolar
disorders. Br J Psychiatry. 2006;188(4):313–20.
19. Kupka RW, Goossens P, van Bendegem M, Daemen P, Daggenvoorde T, Daniels
M, Dols A, van Duin D, Hillgers M, Hoogelander A. Multidisciplinaire richtlijn
bipolaire stoornissen (derde herziene versie). Utrecht: De Tijdstroom; 2015.
20. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy
for depression. 2nd ed. New York: Guilford Press; 2012.
21. Deckersbach T, Hölzel B, Eisner L, Lazar SW, Nierenberg AA. Mindfulness-based
cognitive therapy for bipolar disorder. New York: The Guilford Press; 2014.
22. Khoury B, Lecomte T, Fortin G, Masse M, Therien P, Bouchard V, Chapleau
M, Paquin K, Hofmann SG. Mindfulness-based therapy: a comprehensive
meta-analysis. Clin Psychol Rev. 2013;33(6):763–71.
23. Kuyken W, Warren F, Taylor RS, Whalley B, Crane C, Bondolfi G, Hayes R,
Huijbers MJ, Ma H, Schweizer S, et al. Efficacy and moderators of
mindfulness-based cognitive therapy (MBCT) in prevention of depressive
relapse: an individual patient data meta-analysis from randomized trials.
JAMA Psychiatry. 2016;73(6):565–74.
24. van Aalderen JR, Donders AR, Giommi F, Spinhoven P, Barendregt HP,
Speckens AE. The efficacy of mindfulness-based cognitive therapy in
recurrent depressed patients with and without a current depressive
episode: a randomized controlled trial. Psychol Med. 2012;42(5):989–1001.
25. Strauss C, Cavanagh K, Oliver A, Pettman D. Mindfulness-based interventions for
people diagnosed with a current episode of an anxiety or depressive disorder: a
meta-analysis of randomised controlled trials. PLoS One. 2014;9(4):1–13.
26. Miklowitz DJ, Alatiq Y, Goodwin GM, Geddes JR, Fennell MJV, Dimidjian S,
Hauser M, Williams JMG. A pilot study of mindfulness-based cognitive
therapy for bipolar disorder. Int Assoc Cogn Psychother. 2009;2(4):373–82.
27. Williams JBW, Alatiq Y, Crane C, Barnhofer T, Fennell MJ, Duggan DS,
Hepburn S, Goodwin GM. Mindfulness-based cognitive therapy (MBCT) in
bipolar disorder: preliminary evaluation of immediate effects on between-
episode functioning. JAffectDisord. 2008;107(1–3):275–9.
28. Deckersbach T, Holzel BK, Eisner LR, Stange JP, Peckham AD, Dougherty DD,
Rauch SL, Lazar S, Nierenberg AA. Mindfulness-based cognitive therapy for
nonremitted patients with bipolar disorder. CNS Neurosci Ther. 2012;18(2):
133–41.
Hanssen et al. BMC Psychiatry          (2019) 19:130 Page 9 of 10
29. Weber B, Jermann F, Gex-Fabry M, Nallet A, Bondolfi G, Aubry JM.
Mindfulness-based cognitive therapy for bipolar disorder: a feasibility trial.
Eur Psychiatry. 2010;25(6):334–7.
30. Perich T, Manicavasagar V, Mitchell PB, Ball JR, Hadzi-Pavlovic D. A
randomized controlled trial of mindfulness-based cognitive therapy for
bipolar disorder. Acta Psychiatr Scand. 2013;127(5):333–43.
31. Gu J, Strauss C, Bond R, Cavanagh K. How do mindfulness-based cognitive
therapy and mindfulness-based stress reduction improve mental health and
wellbeing? A systematic review and meta-analysis of mediation studies. Clin
Psychol Rev. 2015;37:1–12.
32. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders (DSM-5®). 5th ed. Arlington, VA: American Psychiatric
Association; 2013.
33. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview
for the DSM-IV Axis I disorders (SCID-I). New York: Biometric Research; 1996.
34. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania:
reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429–35.
35. Good practice guidance for teaching mindfulness-based courses [http://www.
bangor.ac.uk/mindfulness/documents/MBA%20teacherGPG-Feb%2010.pdf].
36. Crane RS, Kuyken W, Williams JMG, Hastings RP, Cooper L, Fennell MJV.
Competence in teaching mindfulness-based courses: concepts,
development and assessment. Mindfulness. 2012;3:76–84.
37. Crane RS, Eames C, Kuyken W, Hastings RP, Williams JMG, Bartley T, Evans A,
Silverton S, Soulsby JG, Surawy C. Development and validation of the
mindfulness-based interventions–teaching assessment criteria (MBI:TAC).
Assessment. 2013;20(6):681–8.
38. Akkerhuis GW. Vertaling IDS. Utrecht, H.C. Rümke Groep; 1997.
39. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon
ML, Shores-Wilson K, Toprac MG, Dennehy EB, et al. The inventory of
depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR),
and the quick inventory of depressive symptomatology, clinician rating
(QIDS-C) and self-report (QIDS-SR) in public sector patients with mood
disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82.
40. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the structured
clinical interview for DSM-IV Axis I disorders (SCID I) and Axis II disorders
(SCID II). Clin Psychol Psychother. 2011;18(1):75–9.
41. Kupka RW, Akkerhuis GW, Nolen WA, Honig A. De life-chartmethode voor de
manisch-depressieve stoornis. Tijdschrift voor Psychiatrie. 1997;39(3):232–9.
42. Altman G, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania
scale. Soc Biol Psychiatry. 1997;42:948–55.
43. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN,
Markowitz JC, Ninan PT, Kornstein S, Manber R, et al. The 16-item quick
inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C),
and self-report (QIDS-SR): a psychometric evaluation in patients with
chronic major depression. Biol Psychiatry. 2003;54(5):573–83.
44. Spielberger CD. Manual for the state-trait anxiety inventory. Palo Alto, CA:
Consulting Psychologists Press; 1983.
45. Van der Ploeg H. Een Nederlandse bewerking van de Spielberger State-Trait
Anxiety Inventory. Lisse: Swets & Zeitlinger; 2000.
46. Rosa AR, Martínez-Aran A, Torrent C, Vieta E, Kapczinski F, Colom F, Ayuso-
Mateos JL, Sánchez-Moreno J, Salamero M, Reinares M. Validity and
reliability of the functioning assessment short test (FAST) in bipolar disorder.
Clin Pract Epidemiol Ment Health. 2007;3(1):5.
47. Lamers S, Westerhof GJ, Bohlmeijer ET, ten Klooster PM, Keyes CLM.
Evaluating the psychometric properties of the mental health continuum-
short form (MHC-SF). J Clin Psychol. 2011;67(1):99–110.
48. Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: a
psychometric analysis. Cogn Ther Res. 2003;27:247–59.
49. Bohlmeijer E, ten Klooster PM, Fledderus M, Veehof M, Baer R. Psychometric
properties of the five facet mindfulness questionnaire in depressed adults
and development of a short form. Assessment. 2011;18(3):308–20.
50. Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial
validation of a short form of the self-compassion scale. Clin Psychol
Psychother. 2011;18(3):250–5.
51. EuroQol Group: EQ-5D-5L. In.; 2009.
52. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L,
Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L
compared to the EQ-5D-3L across eight patient groups: a multi-country
study. Qual Life Res. 2013;22(7):1717–27.
53. Hakkaart VR, L, Van Straten A, Donker M, Tiemens B: Trimbos/iMTA
questionnaire for costs associated with psychiatric illness (TIC-P). Institute for
Medical Technology Assessment, Erasmus University Rotterdam Trimbos 2002.
54. Bouwmans C, de Jong K, Timman R, Zijlstra-Vlasveld M, van der Feltz-Cornelis
C, Swan Tan S, Hakkaart-van Roijen L. Feasibility, reliability and validity of a
questionnaire on healthcare consumption and productivity loss in patients
with a pscyhiatric disorder (TiC-P). BMC Health Serv Res. 2013;13:1–9.
55. Lindahl JR, Fisher NE, Cooper DJ, Rosen RK, Britton WB. The varieties of
contemplative experience: a mixed-methods study of meditation-related
challenges in Western Buddhists. PLoS One. 2017;12(5):e0176239.
56. Dobkin PL, Irving JA, Amar S. For whom may participation in a
mindfulness-based stress reduction program be contraindicated?
Mindfulness. 2012;3:44–50.
57. Shapiro DH. Adverse effects of meditation: a preliminary investigation of
long-term mediators. Int J Psychosom. 1992;39(1–4):62–7.
58. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. Biomedical Central
Med. 2010;8(18):1–9.
59. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman
& Hall; 1993.
60. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing
and comparing indirect effects in multiple mediator models. Behav Res
Methods. 2008;40(3):879–91.
61. Tan SS, Bouwmans-Frijters CAM, Hakkaart-van Roijen L. Handleiding voor
kostenonderzoek: methoden en referentieprijzen voor economische
evaluaties in de gezondheidszorg. Tijdschrift voor
gezondheidswetenschappen. 2012;90(6):367–72.
62. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M,
Orlewska E, Watkins J, Trueman P. Principles of good practice for budget
impact analysis: report of the ISPOR task force on good research
practices—budget impact analysis. Value Health. 2007;10(5):336–47.
63. Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M,
Orlewska E, Penna P, Barrios JR, Shau W. Budget impact analysis—principles
of good practice: report of the ISPOR 2012 budget impact analysis good
practice II task force. Value Health. 2014;17(1):5–14.
64. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic
evaluation. Oxford: Handbooks in Health Economic; 2006.
65. Caro JJ, Briggs AH, Siebert U, Kuntz KM. ISPOR-SMDM modeling good
research practices task force. Modeling good research practices--overview: a
report of the ISPOR-SMDM modeling good research practices task force--1.
Value Health. 2012;15(6):796–803.
66. Format Budget Impact Analyse [https://www.zorginstituutnederland.nl/
publicaties/publicatie/2016/04/06/format-budget-impact-analyse-gvs-
voorheen-kostenconsequentieraming].
Hanssen et al. BMC Psychiatry          (2019) 19:130 Page 10 of 10
